Loading company…
Tyligand develops small-molecule drugs for tumors and immune diseases.
Founded in 2018 and based in Shanghai, Tyligand develops small-molecule drugs for tumors and immune diseases, with research covering lung cancer, colorectal cancer, hormone-driven tumors, and other solid tumors. In July 2023, it raised Series A+ funding as part of a larger USD 20 million Series A round led by Ming Bioventures, with other investors including Bohe Angel Fund, China Medical System Holdings, Calor Capital, Harvest Capital, Shengdi Investment, and Taikun Fund.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in